Mirta Tad (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes 5‑HT2 and 5‑HT3 receptors while stimulating 5‑HT1A receptors. This combined action enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirta Tad is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient-specific factors.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant or nursing should discuss treatment options with their healthcare provider.

To request Mirta Tad, submit an enquiry on the product page at gnhindia.com, specifying the desired quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss. However, its side‑effect profile differs, and choice of therapy should be individualized.

Mirta Tad should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat to maintain product stability.

Mirta Tad is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include the potential for agranulocytosis, severe hypersensitivity reactions, serotonin syndrome when combined with other serotonergic drugs, and worsening depression or emergence of suicidal thoughts. Immediate medical attention is required if any of these occur.

Mirta Tad is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and it should be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with a history of severe serotonin syndrome. Caution is also advised for patients with significant hepatic impairment.